Ann: Becoming a substantial holder, page-11

Cuprum
My tomorrows did not terminate our EAP for fun it was done pure and simple because the drug was manufactured by another company and not the ooriginal manufacturer

i am not saying this is the cause but that is what happend in our EAP for 1102/1103 the last time around so it is obviously a critical factor

i want to know when our drug even in animal studies for Lukemiea in mice has been seen to down regulate cd49d

This is the big factor for me DID IT or DID IT NOT down regulate our target as it has been shown to do in every trial it has been tested in see below

Not only human trials in MS and DMD but as i said see below

A Novel CD49d Targeting Antisense, ATL1102, Effectively Mobilizes Acute Myeloid Leukemia Cells



https://www.sciencedirect.com/science/article/pii/S0006497118507977

QUESTION TO THE BOARD

DID WE OR DIDNT WE SEE ANY CHANGE IN OUR TARGET